CURALOGIC BEGINS TRIAL OF ITS RAGWEED ALLERGY PRODUCT

Curalogic has begun dosing the first patients in a Phase III trial with its product for the treatment of ragweed allergy. The trial will be conducted simultaneously in the U.S. and in a number of European countries, and a total of 550 patients will be enrolled into the study by the end of May.

Top line results from the trial are expected to be released in the first quarter of 2008, and the company plans to submit an application for registration in Europe in the second half of 2008. The RPE 04 trial is the first of two trials needed for submission of an application for registration in the U.S.

The RPE 04 trial is a randomized, double-blind, placebo-controlled study. The purpose of the trial is to evaluate the efficacy and safety of a single daily dose of ragweed pollen extract administered orally to patients who are allergic to ragweed.

Patients with moderate to severe ragweed allergy will be treated daily with an active dose or placebo. Treatment will start at least eight weeks prior to the ragweed pollen season and will continue throughout the entire season. The trial's primary objective is to evaluate the efficacy measured as a total allergy symptom score.